{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:07:58Z","timestamp":1792858078940,"version":"4.5.0"},"reference-count":86,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Heart failure (HF) is a major socioeconomic problem worldwide, associated with high morbidity and mortality due to several underlying diseases. HF is driven by several closely linked mechanisms whose effects are mutually reinforcing. Some of the signalling pathways involved in the progression of HF may initially be compensatory, such as the renin\u2013angiotensin\u2013aldosterone system (RAAS), whose hyperactivation plays a central role in the progression of HF by promoting fluid retention, inflammation, oxidative stress (OS), and myocardial dysfunction. Fluid retention is also promoted by the action of neprilysin, which contrasts natriuresis and vasodilation. Among the compensatory and subsequently maladaptive systems, chronic hyperactivation of the sympathetic nervous system (SNS) exacerbates maladaptive remodelling and drives the progression of HF. At the molecular level, mitochondrial dysfunction and inflammatory substances are involved in the development of a state of systemic oxidative stress and inflammation. The aim of the following manuscript was to revise the pathophysiology and role of OS in HF, focusing on the current knowledge of the molecular pathways involved.<\/jats:p>","DOI":"10.3390\/ijms26115165","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T06:30:26Z","timestamp":1748413826000},"page":"5165","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Implications of Oxidative Stress in the Pathophysiological Pathways of Heart Failure"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-2154","authenticated-orcid":false,"given":"Andrea","family":"D\u2019Amato","sequence":"first","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cesti\u00e8","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7113-7656","authenticated-orcid":false,"given":"Federico","family":"Ferranti","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Segato","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Prosperi","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8721-3459","authenticated-orcid":false,"given":"Rosanna","family":"German\u00f2","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Myftari","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-3059","authenticated-orcid":false,"given":"Simona","family":"Bartimoccia","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-4828","authenticated-orcid":false,"given":"Valentina","family":"Castellani","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7887-5961","authenticated-orcid":false,"given":"Roberto","family":"Badagliacca","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-5945","authenticated-orcid":false,"given":"Vittoria","family":"Cammisotto","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-7455","authenticated-orcid":false,"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-4983","authenticated-orcid":false,"given":"Carmine Dario","family":"Vizza","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6211-4482","authenticated-orcid":false,"given":"Paolo","family":"Severino","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"D\u2019Amato, A., Prosperi, S., Severino, P., Myftari, V., Labbro Francia, A., Cesti\u00e8, C., Pierucci, N., Marek-Iannucci, S., Mariani, M.V., and German\u00f2, R. (2024). Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031574"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","article-title":"Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week","volume":"81","author":"Greene","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","article-title":"Oxidative stress and heart failure","volume":"301","author":"Tsutsui","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ejhf.1320","article-title":"Treating oxidative stress in heart failure: Past, present and future","volume":"21","author":"Voors","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wr\u00f3bel-Nowicka, K., Wojciechowska, C., Jache\u0107, W., Zalewska, M., and Romuk, E. (2024). The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure. Medicina, 60.","DOI":"10.3390\/medicina60050760"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9829505","DOI":"10.1155\/2022\/9829505","article-title":"Oxidative Stress and Heart Failure: Mechanisms, Signalling Pathways, and Therapeutics","volume":"2022","author":"Pagan","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Severino, P., D\u2019Amato, A., Prosperi, S., Myftari, V., Canuti, E.S., Labbro Francia, A., Cesti\u00e8, C., Maestrini, V., Lavalle, C., and Badagliacca, R. (2023). Heart Failure Pharmacological Management: Gaps and Current Perspectives. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031020"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"D\u2019Amato, A., Prosperi, S., Severino, P., Myftari, V., Correale, M., Perrone Filardi, P., Badagliacca, R., Fedele, F., Vizza, C.D., and Palazzuoli, A. (2024). MicroRNA and Heart Failure: A Novel Promising Diagnostic and Therapeutic Tool. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247560"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11897-011-0081-5","article-title":"Pharmacologic strategies to target oxidative stress in heart failure","volume":"9","author":"Ahmed","year":"2012","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10557-017-6752-z","article-title":"Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets","volume":"31","author":"Ayoub","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/2047487319870344","article-title":"Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies","volume":"27","author":"Aimo","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Manolis, A.A., Manolis, T.A., and Manolis, A.S. (2023). Neurohumoral Activation in Heart Failure. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015472"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Reina-Couto, M., Afonso, J., Carvalho, J., Morgado, L., Ronchi, F.A., de Oliveira Leite, A.P., Dias, C.C., Casarini, D.E., Bettencourt, P., and Albino-Teixeira, A. (2021). Interrelationship between renin-angiotensin-aldosterone system and oxidative stress in chronic heart failure patients with or without renal impairment. Biomed. Pharmacother., 133.","DOI":"10.1016\/j.biopha.2020.110938"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: A review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund","year":"2016","journal-title":"Heart"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccl.2013.09.010","article-title":"The sympathetic nervous system and heart failure","volume":"32","author":"Zhang","year":"2014","journal-title":"Cardiol. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1161\/CIRCRESAHA.114.302589","article-title":"The autonomic nervous system and heart failure","volume":"114","author":"Florea","year":"2014","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10741-023-10345-y","article-title":"The sympathetic nervous system in heart failure revisited","volume":"29","author":"Triposkiadis","year":"2024","journal-title":"Heart Fail. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bodnar, P., Mazurkiewicz, M., Chwalba, T., Romuk, E., Ciszek-Chwalba, A., Jache\u0107, W., and Wojciechowska, C. (2023). The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress-Role of New Drugs, Flozins. Biomedicines, 11.","DOI":"10.3390\/biomedicines11082236"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.33160\/yam.2018.06.002","article-title":"Angiotensin II, Oxidative Stress, and Sympathetic Nervous System Hyperactivity in Heart Failure","volume":"61","author":"Koba","year":"2018","journal-title":"Yonago Acta Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.31083\/j.rcm2507270","article-title":"Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction","volume":"25","author":"Palazzuoli","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Prosperi, S., D\u2019Amato, A., Labbro Francia, A., Monosilio, S., Cesti\u00e8, C., Marek Iannucci, S., Netti, L., Angotti, D., Filomena, D., and Mariani, M.V. (2024). Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Different Scenarios of Heart Failure: An Overview of the Current Literature. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111458"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Prosperi, S., D\u2019Amato, A., Severino, P., Myftari, V., Monosilio, S., Marchiori, L., Zagordi, L.M., Filomena, D., Di Pietro, G., and Birtolo, L.I. (2023). Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813848"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10741-021-10170-1","article-title":"Sodium-glucose cotransporter 2 inhibitors and heart failure: The best timing for the right patient","volume":"28","author":"Severino","year":"2023","journal-title":"Heart Fail. Rev."},{"key":"ref_26","first-page":"4121","article-title":"The effects of SGLT-2 inhibitors on echocardiographic indices and antioxidative properties in patients with heart failure with reduced ejection fraction and diabetes mellitus","volume":"28","author":"Duzen","year":"2024","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-023-01822-7","article-title":"Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: Comparative review","volume":"22","author":"Hoehlschen","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_29","first-page":"349","article-title":"The influence of SGLT2 inhibitors on oxidative stress in heart failure and chronic kidney disease in patients with type 2 diabetes","volume":"74","author":"Nabrdalik","year":"2023","journal-title":"Endokrynol. Pol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kamezaki, M., Kusaba, T., Komaki, K., Fushimura, Y., Watanabe, N., Ikeda, K., Kitani, T., Yamashita, N., Uehara, M., and Kirita, Y. (2018). Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-22229-5"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000499597","article-title":"Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus","volume":"49","author":"Woods","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-017-0660-3","article-title":"Role of inflammation in heart failure","volume":"19","author":"Shirazi","year":"2017","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bcp.2006.04.011","article-title":"NF-\u03baB Activation by Reactive Oxygen Species: Fifteen Years Later","volume":"72","author":"Gloire","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.HYP.0000032031.30374.32","article-title":"Activation of NADPH Oxidase During Progression of Cardiac Hypertrophy to Failure","volume":"40","author":"Li","year":"2002","journal-title":"Hypertension"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.107.101980","article-title":"Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction","volume":"51","author":"Looi","year":"2008","journal-title":"Hypertension"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/heartjnl-2012-301952","article-title":"Different Behaviour of NOX2 Activation in Patients with Paroxysmal\/Persistent or Permanent Atrial Fibrillation","volume":"98","author":"Cangemi","year":"2012","journal-title":"Heart"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/thoraxjnl-2015-207178","article-title":"Nox2 Up-Regulation is Associated with an Enhanced Risk of Atrial Fibrillation in Patients with Pneumonia","volume":"70","author":"Violi","year":"2015","journal-title":"Thorax"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0735-1097(01)01377-8","article-title":"Nuclear Factor Kappa-B and the Heart","volume":"38","author":"Valen","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1172\/JCI116834","article-title":"Cellular Basis for the Negative Inotropic Effects of Tumor Necrosis Factor-Alpha in the Adult Mammalian Heart","volume":"92","author":"Yokoyama","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11886-018-1067-7","article-title":"Tumor Necrosis Factor-\u03b1 in Heart Failure: An Updated Review","volume":"20","author":"Schumacher","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_41","first-page":"173","article-title":"Role of Mitogen-Activated Protein Kinase in Cardiac Hypertrophy and Heart Failure","volume":"8","author":"Zhang","year":"2003","journal-title":"Exp. Clin. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Yang, Z., Wang, S., Wang, X., and Mao, J. (2024). Targeting MAPK-ERK\/JNK Pathway: A Potential Intervention Mechanism of Myocardial Fibrosis in Heart Failure. Biomed. Pharmacother., 173.","DOI":"10.1016\/j.biopha.2024.116413"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0008-6363(02)00723-X","article-title":"Sustained Activation of Nuclear Factor Kappa B and Activator Protein 1 in Chronic Heart Failure","volume":"57","author":"Frantz","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1074\/jbc.273.4.2161","article-title":"Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen Activated Protein Kinase Family","volume":"273","author":"Wang","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1096\/fj.99-0671com","article-title":"The Role of Differential Activation of p38-Mitogen-Activated Protein Kinase in Preconditioned Ventricular Myocytes","volume":"14","author":"Saurin","year":"2000","journal-title":"FASEB J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.CIR.103.5.670","article-title":"Differential Activation of Signal Transduction Pathways in Human Hearts with Hypertrophy Versus Advanced Heart Failure","volume":"103","author":"Haq","year":"2001","journal-title":"Circulation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.trsl.2020.11.006","article-title":"Brain-derived neurotrophic factor in patients with acute coronary syndrome","volume":"231","author":"Montone","year":"2021","journal-title":"Transl. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"16353","DOI":"10.20452\/pamw.16353","article-title":"Brain-derived neurotrophic factor and heart failure: A promising new road to explore?","volume":"132","author":"Rinaldi","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1527-5299.2002.00714.x","article-title":"Oxidative stress and endothelial dysfunction in heart failure","volume":"8","author":"Sharma","year":"2002","journal-title":"Congest. Heart Fail."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2011.11.082","article-title":"Endothelial dysfunction, arterial stiffness, and heart failure","volume":"60","author":"Marti","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: The role of endothelial dysfunction and inflammation","volume":"18","author":"Damman","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Alem, M.M. (2019). Endothelial Dysfunction in Chronic Heart Failure: Assessment, Findings, Significance, and Potential Therapeutic Targets. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133198"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1161\/01.CIR.100.19.1983","article-title":"Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: Role of tumor necrosis factor-alpha","volume":"100","author":"Agnoletti","year":"1999","journal-title":"Circulation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of Vericiguat vs. Placebo on Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10741-019-09881-3","article-title":"Role of endothelial dysfunction in heart failure","volume":"25","author":"Zuchi","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10741-012-9340-0","article-title":"Mitochondrial dysfunction in heart failure","volume":"18","author":"Rosca","year":"2013","journal-title":"Heart Fail Rev."},{"key":"ref_59","first-page":"1305","article-title":"Targeting mitochondrial dysfunction in the treatment of heart failure. Expert Rev","volume":"14","author":"Sabbah","year":"2016","journal-title":"Cardiovasc. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCRESAHA.124.323800","article-title":"Mitochondrial Structure and Function in Human Heart Failure","volume":"135","author":"Hinton","year":"2024","journal-title":"Circ. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"106038","DOI":"10.1016\/j.phrs.2021.106038","article-title":"Mitochondrial dysfunction and mitochondrial therapies in heart failure","volume":"175","author":"Wu","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10741-016-9531-1","article-title":"Mitochondrial involvement in myocyte death and heart failure","volume":"21","author":"Goldenthal","year":"2016","journal-title":"Heart Fail. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Bisaccia, G., Ricci, F., Gallina, S., Di Baldassarre, A., and Ghinassi, B. (2021). Mitochondrial Dysfunction and Heart Disease: Critical Appraisal of an Overlooked Association. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020614"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Gallo, G., Rubattu, S., and Volpe, M. (2024). Mitochondrial Dysfunction in Heart Failure: From Pathophysiological Mechanisms to Therapeutic Opportunities. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052667"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial dysfunction in pathophysiology of heart failure","volume":"128","author":"Zhou","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","article-title":"Expert consensus document: Mitochondrial function as a therapeutic target in heart failure","volume":"14","author":"Brown","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.118.036259","article-title":"Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction","volume":"139","author":"Kumar","year":"2019","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.freeradbiomed.2018.09.019","article-title":"Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities","volume":"129","author":"Kiyuna","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/nrcardio.2014.189","article-title":"Heart failure: Mitochondrial dysfunction and oxidative stress in CHF","volume":"12","author":"Okonko","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jchf.2014.06.008","article-title":"The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: Results from Q-SYMBIO: A Randomized Double-Blind Trial","volume":"2","author":"Mortensen","year":"2014","journal-title":"JACC Heart Fail."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.18087\/cardio.2022.6.n2050","article-title":"Coenzyme Q-10 in the Treatment of Patients with Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction: Systematic Review and Meta-Analysis","volume":"62","author":"Mareev","year":"2022","journal-title":"Kardiologiia"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Hope and HOPE-TOO Trial Investigators (2005). Effects of Long-Term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial. JAMA, 293, 1338\u20131347.","DOI":"10.1001\/jama.293.11.1338"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/ajcn\/73.2.219","article-title":"A Controlled Clinical Trial of Vitamin E Supplementation in Patients with Congestive Heart Failure","volume":"73","author":"Keith","year":"2001","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ye, Y., Li, J., and Yuan, Z. (2013). Effect of Antioxidant Vitamin Supplementation on Cardiovascular Outcomes: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056803"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 Polyunsaturated Fatty Acids in Patients with Chronic Heart Failure (The GISSI-HF Trial): A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Oppedisano, F., Mollace, R., Tavernese, A., Gliozzi, M., Musolino, V., Macr\u00ec, R., Carresi, C., Maiuolo, J., Serra, M., and Cardamone, A. (2021). PUFA supplementation and heart failure: Effects on fibrosis and cardiac remodeling. Nutrients, 13.","DOI":"10.3390\/nu13092965"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100366","DOI":"10.1016\/j.advnut.2025.100366","article-title":"The optimal dosage and duration of \u03c9-3 PUFA supplementation in heart failure management: Evidence from a network meta-analysis","volume":"16","author":"Tseng","year":"2025","journal-title":"Adv. Nutr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: Executive summary","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_79","first-page":"202","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"25","author":"McDonagh","year":"2024","journal-title":"G. Ital. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 69, 89\u201395.","DOI":"10.1067\/mcp.2001.113989"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Ng, M.L., Ang, X., Yap, K.Y., Ng, J.J., Goh, E.C.H., Khoo, B.B.J., Richards, A.M., and Drum, C.L. (2023). Novel oxidative stress biomarkers with risk prognosis values in heart failure. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030917"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1161\/01.CIR.97.16.1536","article-title":"Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: A potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure","volume":"97","author":"Mallat","year":"1998","journal-title":"Circulation"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1179\/135100008X259204","article-title":"Markers of oxidative damage in chronic heart failure: Role in disease progression","volume":"13","author":"Radovanovic","year":"2008","journal-title":"Redox Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejim.2016.09.011","article-title":"Heart failure and anemia: Effects on prognostic variables","volume":"37","author":"Cattadori","year":"2017","journal-title":"Eur J Intern Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/ehf2.15172","article-title":"Implementation of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa-HF Registry)","volume":"12","author":"Paolillo","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/0115701611334141241217044516","article-title":"The Early Pharmacological Strategy with Inodilator, bEta-blockers, Mineralocorticoid Receptor Antagonists, Sodium-glucose coTransporter-2 Inhibitors and Angiotensin Receptor-neprylisin Inhibitors in Acute Heart Failure (PENTA-HF)","volume":"23","author":"Severino","year":"2025","journal-title":"Curr. Vasc. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5165\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:41:56Z","timestamp":1760031716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":86,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115165"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115165","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}